Scancell Holdings plc (LON:SCLP – Get Free Report)’s share price crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 13.34 ($0.17) and traded as low as GBX 8.84 ($0.11). Scancell shares last traded at GBX 8.84 ($0.11), with a volume of 979,057 shares.
Scancell Stock Performance
The firm has a market cap of £91.60 million, a price-to-earnings ratio of -13.56 and a beta of 0.35. The stock’s fifty day moving average is GBX 10.07 and its two-hundred day moving average is GBX 13.32. The company has a debt-to-equity ratio of -566.79, a quick ratio of 13.01 and a current ratio of 3.42.
Scancell (LON:SCLP – Get Free Report) last released its quarterly earnings results on Thursday, January 30th. The company reported GBX (1.35) (($0.02)) earnings per share for the quarter. On average, analysts expect that Scancell Holdings plc will post -2.5361112 earnings per share for the current fiscal year.
About Scancell
Scancell (LSE:SCLP) is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.
Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.
Recommended Stories
- Five stocks we like better than Scancell
- Dividend Capture Strategy: What You Need to Know
- Symbotic Shares Down 37%—Is It Time for Bravery or Caution?
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- High-Yield Healthcare: 3 Stocks With Strong Dividends
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Beyond the Bargain Bin: 3 Stocks Leading Discount Retail
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.